Please read this leaflet carefully. It provides some information about your medicine. If you have any questions or are not sure about anything after you have read this leaflet, please ask your doctor or pharmacist.

The name of your medicine is Somatuline® Autogel®. Somatuline Autogel is a solution for injection in a pre-filled syringe, ready to use and fitted with an automatic safety system. It is a white to pale yellow semi-solid formulation. The active substance is lanreotide. The dose of lanreotide you will receive is 60, 90 or 120 mg. There is an extra amount filled into the syringe to ensure that the correct dose can be injected. The other ingredients are sterile water and acetic acid.

The product is for single use only.

Somatuline Autogel is a prolonged release formulation of lanreotide. Lanreotide is an octapeptide, an analogue of a naturally occurring hormone, somatostatin. Lanreotide lowers the levels of hormones in the body such as GH (growth hormone) and IGF-1 (insulin-like growth factor-1).

Somatuline Autogel is used for the treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy, or in patients who do not respond to therapy with drugs called dopamine agonists.

Somatuline Autogel is used for the treatment of symptoms associated with carcinoid syndrome, such as flushing and diarrhoea.

Somatuline Autogel is used for the treatment and control of the growth of some advanced tumours of the intestine and pancreas that cannot be removed by surgery (called gastroenteropancreatic neuroendocrine tumours or GEP-NETs).

Do not be given Somatuline Autogel if:

Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.

Some medicines and Somatuline Autogel may interfere with each other. Somatuline Autogel may reduce the intestinal absorption of other drugs administered at the same time (e.g. cyclosporin A) or increase the bioavailability of bromocriptine. The dose of other drugs which reduce the heart rate (e.g. beta-blockers) may need to be reduced if Somatuline Autogel is administered.

Somatuline Autogel may interfere with the breakdown of some drugs by the liver enzymes (e.g. quinidine or terfenadine).

Your doctor or pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

Somatuline Autogel is intended for deep injection under the skin. It is for single use only. It should be injected as described in the instructions in this leaflet.

For the treatment of acromegaly or the symptoms of carcinoid syndrome, the recommended starting dose is 60 mg to 120 mg injected every 28 days. Depending on your response to the product, your doctor may vary the dose or the injection frequency. Your doctor will also decide on the length of your treatment.

If you are controlled on Somatuline Autogel for the treatment of acromegaly or the symptoms of carcinoid syndrome, your doctor may suggest that the injection can be given by yourself or your carer. Your doctor or nurse will give you or your carer the appropriate training and confirm that you are both motivated and capable of doing this. Your doctor will continue to supervise the long-term management of your condition.

If the injection is being administered by a healthcare professional or your carer, the injection will usually be given as a deep subcutaneous injection in the upper, outer external quadrant of the buttock.

If you are giving the injection to yourself, the deep subcutaneous injection should be given in the upper, outer thigh.

The injection site should be alternated between right and left sides.

For the treatment of advanced tumours of the intestine and pancreas that cannot be removed by surgery (gastroenteropancreatic neuroendocrine tumours - GEP-NETs), the recommended dose is 120mg every 28 days. Your doctor will decide how long you should be treated with Somatuline Autogel for tumour control.

As soon as you realise that you have missed an injection, contact your doctor who will then advise when your next injection is to be given.

The following side effects have been reported as common or very common in patients receiving Somatuline Autogel injections:

If you are diabetic, your doctor may check your blood sugar levels and possibly alter your anti-diabetic treatment while you are receiving Somatuline Autogel.

If you have heart problems, your doctor may check your heart rate and possibly alter your treatment while you are taking Somatuline Autogel.

Due to the possibility of gallbladder problems with this type of medicine, your doctor may want to conduct a gallbladder scan when you start receiving Somatuline Autogel and again at regular intervals thereafter.

These might be the result of an allergic reaction. The frequency of these side effects is not known; it cannot be estimated from the available data.

If any side effect is troublesome or causes any concern, you should tell your doctor or pharmacist.

As Somatuline Autogel is given to you under the supervision of your doctor, it is very unlikely that you will receive too much. Somatuline Autogel comes in a syringe pre-filled with the dose your doctor has prescribed. However, if you feel you have been given too much Somatuline Autogel, contact the Poisons Information Centre on 131126 for advice.

Store Somatuline Autogel at 2°C-8°C in a refrigerator in its original package. Do not freeze. Keep it out of the reach and sight of children.

DO NOT USE AFTER THE EXPIRY DATE SHOWN ON THE LABELS AND BOX.

DO NOT USE IF THE LAMINATED POUCH IS DAMAGED OR OPENED.

Each Somatuline Autogel pre-filled syringe is packed in a pouch and a cardboard box.

Each box contains one 0.5 mL syringe with an automatic safety system and one needle (1.2 mm x 20 mm).

Somatuline Autogel 60 mg contains lanreotide acetate 60 mg as the active ingredient.

Somatuline Autogel 90 mg contains lanreotide acetate 90 mg as the active ingredient.

Somatuline Autogel 120 mg contains lanreotide acetate 120 mg as the active ingredient.

The other ingredients are sterile water and acetic acid.